Frazier Life Sciences is a venture capital and public equity investment firm focused on biopharmaceuticals, partnering with and building companies developing novel therapeutics from company creation through public markets. The firm closed its latest venture fund at $1.3 billion in 2025.
51% of their portfolio is in Biotech & Life Sciences. Deal activity increased 50% year-over-year (15 deals in the last 12 months). Average disclosed round size is $125.5M (across 78 rounds with reported amounts).
Portfolio
62
Fund Size
$1.3B
Top Stage
Series A
Last 12 Mo
15
Team
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
82 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Braveheart Bio | Unknown | $185M | Sep 2026 |
 Crystalys Therapeutics Inc | Series B | $130M | Jul 2026 |
 RQ Biotechnology | Series A | $115M | Jun 2026 |
 cAMPfield Therapeutics | Series A | $180M | Jun 2026 |
| CcAMPfield | Series A | $180M | Jun 2026 |
 Sidewinder | Series B | $137M | Apr 2026 |
 Immutrin | Series A | $87M | Mar 2026 |
| VVima Therapeutics, Inc. | Series A | $40M | Mar 2026 |
| VVima | Series A | $100M | Mar 2026 |
| SSidewinder Therapeutics | Series B | $137M | Jan 2026 |
| Sidewinder | Series B | $137M | Jan 2026 |
| RQ Biotechnology | Series A | $115M | Jan 2026 |
| AAngitia Bio | Series D | $130M | Jan 2026 |
| PParabilis | Series F | $305M | Jan 2026 |
| AAirNexis | Series A | $200M | Jan 2026 |
| CcAMPfield | Series A | $180M | Jan 2026 |
| VVima Therapeutics, Inc. | Unknown | $40M | Jan 2026 |
 Parabilis Medicines | Series F | $305M | Jan 2026 |
| Braveheart Bio | Unknown | $185M | Jan 2026 |
| Immutrin | Series A | $87M | Jan 2026 |
 Angitia Biopharmaceuticals | Series D | $130M | Jan 2026 |
 Diagonal Therapeutics | Series B | $125M | Jan 2026 |
 Iolyx Therapeutics | Series B | $15M | Dec 2025 |
 Aspen Neuroscience | Series C | $115M | Nov 2025 |
 Aspen Neuroscience | Series C | $115M | Nov 2025 |
Page 1 of 4
Top Co-Investors
RA Capital Management26 shared
Frazier Healthcare Partners26 shared
OrbiMed22 shared
Deep Track Capital17 shared
Longitude Capital16 shared
Samsara BioCapital15 shared
Wellington Management14 shared
Logos Capital11 shared
Novo Capital10 shared
Lightspeed Venture Partners10 shared
Cormorant Asset Management9 shared
Nextech Invest Ltd.8 shared
Alexandria Venture Investments8 shared
Forbion8 shared
Novo Holdings A/S7 shared
Sanofi Ventures7 shared
Enavate Sciences7 shared
Soleus Capital6 shared
ARCH Venture Partners6 shared
Last updated: 20 October 2026